SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair

Figure 5

SN-38 enhances the antitumor efficacy of olaparib in an A2780 subcutaneous xenograft model. Mice bearing A2780 xenograft were divided into 4 groups, and each group received 100 mg/kg olaparib, 10 mg/kg SN-38 alone, or their combination; tumor volumes were measured every 5 days. Tumor volumes were measured (a) and tumor growth curve (b) was shown. Tumors were weighed and shown in (c). (d, e) Immunohistochemistry (IHC) analysis of Ki67 in the tumors derived from the 4 groups of mice mentioned above. , , and by 2-tailed -test.

(a)

(b)

(c)

(d)

(e)